EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript
EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript
Seeking Alpha8/14/2026Neutral
FOCL
EDAP TMS S.A.NASDAQHEALTHCAREMEDICAL DISTRIBUTION
Key Statistics
Market Cap
$163.42M
P/E Ratio
—
EPS
$-0.93
Beta
-0.03
52W High
$6.40
52W Low
$1.30
50-Day MA
$5.37
200-Day MA
$3.98
Dividend Yield
—
Profit Margin
-49.10%
Forward P/E
38.91
PEG Ratio
—
About EDAP TMS S.A.
Focal Inc (FOCL) is a pioneering technology firm specializing in augmented reality (AR) and virtual reality (VR) solutions that enhance user engagement across diverse sectors, including gaming, education, and training. With a strong emphasis on innovation and a commitment to high-quality immersive experiences, Focal Inc is strategically positioned to capitalize on the increasing demand for interactive digital environments. Supported by robust research and development, the company is actively expanding its product portfolio and market presence, making it a notable player in the dynamic landscape of immersive technology. As the company continues to advance its initiatives, it is well-placed for substantial growth and value generation in the era of digital transformation.
Fundamentals
| Revenue (TTM) | $79.31M |
| Gross Profit (TTM) | $35.28M |
| EBITDA | $-23.69M |
| Operating Margin | -60.80% |
| Return on Equity | -273.90% |
| Return on Assets | -22.40% |
| Revenue/Share (TTM) | $2.12 |
| Book Value | $0.27 |
| Price-to-Book | 17.22 |
| Price-to-Sales (TTM) | 2.06 |
| EV/Revenue | 3.24 |
| EV/EBITDA | 1165.78 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -28.00% |
| Shares Outstanding | $37.48M |
| Float | $29.75M |
| % Insiders | 6.12% |
| % Institutions | 39.38% |
Historical Volatility
HV 10-Day
130.56%
HV 20-Day
98.23%
HV 30-Day
81.51%
HV 60-Day
64.58%
HV Rank
56.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($8.60 target)
3
Buy2
HoldLatest News
FocalTherics™ Reports Second Quarter 2026 Financial Results
FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial results for the second quarter of 2026. This marks the Company's first reporting period presenting its HIFU business as continuing operations and its ESWL and Distribution businesses as discontinued operations.
GlobeNewsWire8/13/2026Neutral
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic energy-based therapies, announced the pricing of its underwritten public offering of 8,425,000 of American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, €0.13 nominal value per share at a public offering price of $4.75 per ADS, before underwriting discounts and commissions (the “Offering”). All of the ADSs are being sold by the Company.
GlobeNewsWire8/12/2026Neutral
FocalTherics™ Announces Proposed Public Offering of American Depositary Shares
FocalTherics™ Announces Proposed Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic energy-based therapies, announced today that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, €0.13 nominal value per share (the “Offering”). All of the ADSs in the proposed Offering will be sold by the Company.
GlobeNewsWire8/11/2026Neutral
FocalTherics (FOCL) Surges 6.2%: Is This an Indication of Further Gains?
FocalTherics (FOCL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Research8/5/2026Positive
FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026
Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT
GlobeNewsWire7/30/2026Neutral
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
GlobeNewsWire6/30/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FOCL and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026